Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2.

Viruses - 19 Aug 2021

Peiffer-Smadja Nathan, Bridier-Nahmias Antoine, Ferré Valentine Marie, Charpentier Charlotte, Garé Mathilde, Rioux Christophe, Allemand Aude, Lavallée Philippa, Ghosn Jade, Kramer Laura, Descamps Diane, Yazdanpanah Yazdan, Visseaux Benoit

Abstract excerpt

An Emergency Use Authorization was issued in the United States and in Europe for a monoclonal antibody monotherapy to prevent severe COVID-19 in high-risk patients. This study aimed to assess the risk of emergence of mutations following treatment with a single monoclonal antibody. Bamlanivimab was administered at a single dose of 700 mg in a one-hour IV injection in a referral center for the management of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Comorbidity

Share to COVID-19

Share to COVID-19 Drug Treatment

Share to Drug Resistance, Viral

Share to France

Share to SARS-CoV-2

Source

Open in PubMed Open full text

Identifiers

PMID: 34452507
DOI: 10.3390/v13081642
PMCID: PMC8402761

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2.PMID 34452507Read ↗

Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in GermanySemantic proximity Read ↗

Emergence of SARS-CoV-2 Resistance with Monoclonal Antibody TherapySemantic proximity Read ↗

Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial.Semantic proximity Read ↗

Emergence and onward transmission of a SARS-CoV-2 E484K variant among household contacts of a bamlanivimab-treated patient.Semantic proximity Read ↗

Acquisition and onward transmission of a SARS-CoV-2 E484K variant among household contacts of a bamlanivimab-treated patientSemantic proximity Read ↗

Characterisation of the antibody-mediated selective pressure driving intra-host evolution of SARS-CoV-2 in prolonged infection.Semantic proximity Read ↗

Bamlanivimab Treatment Leads to Rapid Selection of Immune Escape Variant Carrying the E484K Mutation in a B.1.1.7-Infected and Immunosuppressed PatientSemantic proximity Read ↗

Variant-specific humoral immune response to SARS-CoV-2 escape mutants arising in clinically severe, prolonged infectionSemantic proximity Read ↗

Clinical and Virological Outcome of Monoclonal Antibody Therapies Across SARS-CoV-2 Variants in 245 Immunocompromised Patients: A Multicenter Prospective Cohort Study.Semantic proximity Read ↗

Genotypic and Predicted Phenotypic Analysis of SARS-CoV-2 Omicron Subvariants in Immunocompromised Patients with COVID-19 Following Tixagevimab-Cilgavimab ProphylaxisSemantic proximity Read ↗

Overcoming Variants Resistance in Monoclonal Antibody for Antiviral TherapySemantic proximity Read ↗

Bamlanivimab does not neutralize two SARS-CoV-2 variants carrying E484K in vitroSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.